<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127710</url>
  </required_header>
  <id_info>
    <org_study_id>D5082C00002</org_study_id>
    <secondary_id>GU 111</secondary_id>
    <nct_id>NCT02127710</nct_id>
  </id_info>
  <brief_title>A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)</brief_title>
  <official_title>A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate
      the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who
      are treatment naïve or previously treated.

      An independent central pathology review of tumour samples will be used to confirm the
      diagnosis of PRCC of all patients enrolling. However, locally available pathology results
      confirming PRCC will be allowed for timely study entry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled.
      This group is considered sufficient to provide preliminary assessment of the anti-tumour
      activity of AZD6094 in the form of non-binding futility analysis.

      If ≤ 2 tumour responses are observed in the first 20 evaluable patients termination of the
      study will be considered taking into account the relevant molecular profile of the patients
      and additional information from related studies in the drug development programme.

      All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD).
      Treatment will be given continuously.

      Following the baseline assessment, efficacy will be assessed by objective tumour assessments
      every 6 weeks (±7 days), for the first 12 months and every 12 weeks thereafter until
      objective disease progression as defined by RECIST v1.1 There will be a data cut-off after
      all patients have completed at least 12 weeks of treatment with AZD6094 or withdrawn. The
      database will be locked and data analysis will be performed on this dataset.

      Any patients still receiving study drug at the time of data cut-off will be able to continue
      to receive AZD6094 while deriving clinical benefit. Such patients will continue to be
      monitored for the occurrence of serious adverse events up to 28 days after the last dose of
      AZD6094.

      After database lock (DBL) tumour assessments will be performed every 12 weeks (±7 days) until
      objective disease progression as defined by RECIST v1.1.

      Patients discontinuing treatment due to documented disease progression will enter a survival
      follow-up period, where they will be followed for the initiation of subsequent anti-cancer
      therapies every 3 months until death, loss to follow-up or withdrawal of consent, whichever
      comes first.

      Patients discontinuing treatment prior to documented disease progression will enter a
      progression-free survival follow-up period where they will continue to have disease
      assessments every 6 weeks (±7 days) for the first 12 months of follow-up and every 12 weeks
      thereafter until objective disease progression as defined by RECIST v1.1, death, loss to
      follow-up or withdrawal of consent, whichever comes first. After DBL, tumour assessments will
      be performed in the progression free survival patient population every 12 weeks (±7 days)
      until objective disease progression as defined by RECIST v1.1
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">April 14, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate in Efficacy Analysis Set (n = 84)</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate in the Safety Analysis Set (n = 109)</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in the Efficacy Analysis Set (n = 84)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in the Efficacy Analysis Set (n = 84)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in the Safety Analysis Set (n = 109)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in the Safety Analysis Set (n = 109)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Papillary Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>AZD6094 600 mg daily continuously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6094</intervention_name>
    <description>AZD6094 is a potent and selective small molecule cMet kinase inhibitor.</description>
    <arm_group_label>AZD6094 600 mg daily continuously</arm_group_label>
    <other_name>Savolitinib</other_name>
    <other_name>HMPL - 504</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Provision of informed consent prior to any study specific procedures, sampling and
             analyses.

          2. Histologically confirmed papillary renal cell cancer, which is locally advanced or
             metastatic.

          3. Availability of an archival tumor sample or a pre-treatment fresh tumor sample for
             confirmation of PRCC by a central laboratory and other biomarker

          4. Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may
             include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib,
             temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a,
             Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          6. At least one lesion, not previously irradiated, and not chosen for a biopsy if
             performed during the screening period that can be accurately measured at baseline and
             which is suitable for accurate repeated measurements.

          7. Adequate hematological function defined as:

               1. (ANC) ≥1500/μL

               2. (Hgb) ≥9 g/dL

               3. Platelets ≥100,000/μL

          8. Adequate liver function defined as:

               1. ALT and AST ≤2.5 x the upper limit of normal (ULN)

               2. Total bilirubin ≤1.5 x ULN

          9. Adequate renal function defined as glomerular filtration rate (GFR) ≥ 40 mL/min,

         10. Adequate coagulation parameters, defined as International Normalisation Ratio(INR)
             &lt;1.5 x ULN or activated partial thromboplastin time (aPTT) &lt;1.5 x ULN.

         11. Patients with known tumor thrombus or deep vein thrombosis (DVT) are eligible if
             stable on low molecular weight heparin (LMWH) for ≥4 weeks.

         12. Females should be using adequate contraceptive measures should notbe breast feeding,
             and must have a negative pregnancy test prior to start of dosing ifof childbearing
             potential or must have evidence of non-childbearing potential

         13. Male patients should be willing to use barrier contraception, i.e. condoms.

         14. Ability to swallow and retain oral medications.

         15. Predicted life expectancy ≥12 weeks.

         16. Aged at least 18 years.

         17. Willingness and ability to comply with study and follow-up procedures.

         18. Ability to understand the nature of this study and give written informed consent.

        Exclusion criteria

          1. Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational
             agents &lt;21 days of the first dose of study treatment. Most recent targeted therapy &lt;14
             days of the first dose of study treatment.

          2. Unresolved toxicities from any prior therapy greater than Common Terminology Criteria
             for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the
             exception of alopecia.

          3. Prior or current treatment with a cMet inhibitor

          4. Strong inducers or inhibitors of CYP3A4, strong inhibitors of CYP1A2, or CYP3A4
             substrates with a narrow therapeutic range within 2 weeks before the first dose of
             study treatment (3 weeks for St John's Wort)

          5. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89)
             administered ≤28 days or limited field radiation for palliation ≤7 days prior to
             starting study drug or has not recovered from side effects of such therapy

          6. Major surgical procedures ≤28 days of beginning study drug or minor surgical
             procedures ≤7 days. No waiting is required following port-a-cath placement.

          7. Previously untreated brain metastases.

          8. Current leptomeningeal metastases or spinal cord compression due to disease.

          9. Acute or chronic liver or pancreatic disease.

         10. Uncontrolled diabetes mellitus.

         11. Gastrointestinal disease or other condition that will interfere significantly with the
             absorption, distribution, metabolism, or excretion of oral therapy

         12. Any of the following cardiac diseases currently or within the last 6 months:

               1. Unstable angina pectoris

               2. Congestive heart failure (New York Heart Association [NYHA] ≥ Grade 2

               3. Acute myocardial infarction

               4. Stroke or transient ischemic attack

         13. Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] &gt;160 mmHg or
             diastolic blood pressure (DBP) &gt;100 mmHg) (patients with values above these levels
             must have their blood pressure (BP) controlled with medication prior to starting
             treatment).

         14. Mean resting correct QT interval (QTc) &gt;470 msec obtained from triplicate ECGs.

         15. Any clinically important abnormalities in rhythm, conduction or morphology of resting
             electrocardiograms (ECGs), e.g. complete left bundle branch block, third degree heart
             block, second degree heart block, PR interval &gt;250 msec.

         16. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
             such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family
             history of unexplained sudden death under 40 years of age or any concomitant
             medications known to prolong QT interval.

         17. Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular
             weight heparin (LMWH) is allowed.

         18. Serious active infection at the time of treatment, or another serious underlying
             medical condition that would impair the ability of the patient to receive protocol
             treatment.

         19. Known diagnosis of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.

         20. Presence of other active cancers, or history of treatment for invasive cancer ≤5years.
             Patients with Stage I cancer who have received definitive local treatment at least 3
             years previously, and are considered unlikely to recur are eligible. All patients with
             previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are
             patients with history of non-melanoma skin cancer.

         21. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik-Tobias Arkenau, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sarah Cannon Research Institute United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute United Kingdom</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2609&amp;filename=d5082c00002-revised-csp-3_Redacted.pdf</url>
    <description>D5082c00002-revised-csp-3_Redacted</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <results_first_submitted>September 13, 2017</results_first_submitted>
  <results_first_submitted_qc>September 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2017</results_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD6094</keyword>
  <keyword>Savolitinib</keyword>
  <keyword>Papillary Renal Cell Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One hundred thirty-one (131) subjects gave informed consent to be screened; 111 patients were enrolled; 20 patients were screen failures; 109 patients received at least one dose of AZD6094. Two patients were withdrawn prior to receiving any study drug.
The study was conducted at 23 international sites in the US, Canada, UK, and Spain.</recruitment_details>
      <pre_assignment_details>This was an open-label, single-arm, multicentre, global, Phase 2 study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma who were either treatment naïve or previously treated. All patients entering the study took AZD6094 600 mg orally once per day, continuously.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>c-MET Positive</title>
          <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="P2">
          <title>c-MET Negative</title>
          <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="P3">
          <title>c-MET Status Unknown</title>
          <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who received at least one dose of AZD6094 are included in the baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>c-MET Positive</title>
          <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="B2">
          <title>c-MET Negative</title>
          <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="B3">
          <title>c-MET Status Unknown</title>
          <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="12.78"/>
                    <measurement group_id="B2" value="61.1" spread="10.64"/>
                    <measurement group_id="B3" value="57.3" spread="13.82"/>
                    <measurement group_id="B4" value="60.9" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="23" upper_limit="87"/>
                    <measurement group_id="B2" value="64" lower_limit="29" upper_limit="75"/>
                    <measurement group_id="B3" value="58" lower_limit="37" upper_limit="80"/>
                    <measurement group_id="B4" value="64" lower_limit="23" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG Performance Status:
(0) = Fully active; (1) = Restricted in physically strenuous activity; (2) = Ambulatory and capable of self-care; (3) = Capable of limited self-care; (4) = Completely disabled</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PS = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PRCC Confirmation from Central Laboratory</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Cell Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type I papillary RCC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II papillary RCC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MSKCC risk group</title>
          <description>Risk categories for patients were obtained from the Memorial Sloan Kettering Cancer Center (MSKCC) risk category prognostic model in advanced renal cell cancer, as follows: Favourable risk = 0 risk factors; Intermediate risk = 1 or 2 risk factors; Poor risk = 3 or more risk factors. Risk factors include: Karnofsky performance status &lt; 80%; time from diagnosis to salvage treatment &lt; 1 year; haemoglobin &lt; LLN; corrected serum calcium &gt; ULN; and serum LDH &gt; 1.5 x ULN.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Favourable risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate in Efficacy Analysis Set (n = 84)</title>
        <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
        <time_frame>12 Months</time_frame>
        <population>ORR was assessed on the efficacy analysis set, consisting of all patients with measurable disease and papillary renal cell carcinoma confirmed by a central laboratory (n = 84).</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate in Efficacy Analysis Set (n = 84)</title>
          <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
          <population>ORR was assessed on the efficacy analysis set, consisting of all patients with measurable disease and papillary renal cell carcinoma confirmed by a central laboratory (n = 84).</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) in the Efficacy Analysis Set (n = 84)</title>
        <time_frame>12 months</time_frame>
        <population>Progression Free Survival (PFS) was assessed on the efficacy analysis set, consisting of all patients with measurable disease and papillary renal cell carcinoma confirmed by a central laboratory (n = 84)</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) in the Efficacy Analysis Set (n = 84)</title>
          <population>Progression Free Survival (PFS) was assessed on the efficacy analysis set, consisting of all patients with measurable disease and papillary renal cell carcinoma confirmed by a central laboratory (n = 84)</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="12.6" upper_limit="29.7"/>
                    <measurement group_id="O2" value="6.3" lower_limit="6.0" upper_limit="12.4"/>
                    <measurement group_id="O3" value="6.1" lower_limit="5.1" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in the Efficacy Analysis Set (n = 84)</title>
        <time_frame>12 months</time_frame>
        <population>Overall Survival (OS) was assessed on the efficacy analysis set, consisting of all patients with measurable disease and papillary renal cell carcinoma confirmed by a central laboratory (n = 84)</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the Efficacy Analysis Set (n = 84)</title>
          <population>Overall Survival (OS) was assessed on the efficacy analysis set, consisting of all patients with measurable disease and papillary renal cell carcinoma confirmed by a central laboratory (n = 84)</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" lower_limit="27.0">The upper bound of the 95% confidence interval could not be calculated</measurement>
                    <measurement group_id="O2" value="53.7" lower_limit="13.3" upper_limit="56.1"/>
                    <measurement group_id="O3" value="62.9" lower_limit="8.1" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate in the Safety Analysis Set (n = 109)</title>
        <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
        <time_frame>12 Months</time_frame>
        <population>In this analysis ORR was assessed on the safety analysis set, consisting of all patients who received at least one dose of AZD6094 (n = 109).</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate in the Safety Analysis Set (n = 109)</title>
          <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
          <population>In this analysis ORR was assessed on the safety analysis set, consisting of all patients who received at least one dose of AZD6094 (n = 109).</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) in the Safety Analysis Set (n = 109)</title>
        <time_frame>12 months</time_frame>
        <population>In this analysis PFS was assessed on the safety analysis set, consisting of all patients who received at least one dose of AZD6094 (n = 109).</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) in the Safety Analysis Set (n = 109)</title>
          <population>In this analysis PFS was assessed on the safety analysis set, consisting of all patients who received at least one dose of AZD6094 (n = 109).</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="17.9" upper_limit="29.7"/>
                    <measurement group_id="O2" value="6.1" lower_limit="5.9" upper_limit="11.9"/>
                    <measurement group_id="O3" value="11.3" lower_limit="5.9" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in the Safety Analysis Set (n = 109)</title>
        <time_frame>12 months</time_frame>
        <population>In this analysis OS was assessed on the safety analysis set, consisting of all patients who received at least one dose of AZD6094 (n = 109).</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown</title>
            <description>Papillary renal cell carcinoma (PRCC) is divided into two subtypes based upon histological criteria and distinctive gene expression profile: type I (hereditary papillary renal carcinoma [HPRC]) and type II. In HPRC, mutations in the gene encoding the receptor for Hepatocyte Growth Factor (HGF), MET, are associated with the onset of multiple bilateral type I papillary carcinomas; these tumors tend to be low grade and have a better prognosis. Type II lesions are generally high grade and have a poorer prognosis.
All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the Safety Analysis Set (n = 109)</title>
          <population>In this analysis OS was assessed on the safety analysis set, consisting of all patients who received at least one dose of AZD6094 (n = 109).</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="34.0">The upper bound of the 95% confidence interval could not be calculated.</measurement>
                    <measurement group_id="O2" value="42.7" lower_limit="14.1" upper_limit="56.1"/>
                    <measurement group_id="O3" value="62.9" lower_limit="14.9" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD6094 600 mg Per Day Orally</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydarion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyponataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="19" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="86" subjects_affected="57" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="53" subjects_affected="35" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="65" subjects_affected="51" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Peripheral oedema</sub_title>
                <counts group_id="E1" events="70" subjects_affected="35" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="18" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Blood alklaine phosphatase increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="39" subjects_affected="25" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthalgia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dyspnoea on exertion</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Medical Director, Savolitinib</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

